Last reviewed · How we verify
copper histidinate
Copper histidinate provides bioavailable copper to restore deficient copper levels in patients with copper malabsorption or deficiency.
Copper histidinate provides bioavailable copper to restore deficient copper levels in patients with copper malabsorption or deficiency. Used for Copper deficiency due to malabsorption (including Menkes disease and related copper transport disorders).
At a glance
| Generic name | copper histidinate |
|---|---|
| Also known as | CUTX-101 |
| Sponsor | Sentynl Therapeutics, Inc. |
| Drug class | Trace element supplement |
| Target | Copper ion (Cu2+) |
| Modality | Small molecule |
| Therapeutic area | Metabolic/Genetic Disorders |
| Phase | FDA-approved |
Mechanism of action
Copper is an essential trace element required for multiple enzymatic processes including cytochrome c oxidase, lysyl oxidase, and superoxide dismutase. Copper histidinate is a chelate complex that enhances copper absorption in the gastrointestinal tract, allowing systemic copper repletion in patients who cannot adequately absorb dietary copper due to genetic disorders or malabsorption conditions.
Approved indications
- Copper deficiency due to malabsorption (including Menkes disease and related copper transport disorders)
Common side effects
- Gastrointestinal upset
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- copper histidinate CI brief — competitive landscape report
- copper histidinate updates RSS · CI watch RSS
- Sentynl Therapeutics, Inc. portfolio CI